SI
TGTX icon

Sofinnova Investments’s TG Therapeutics TGTX Stock Holding History

Sofinnova Investments’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-358,644
Closed -$8.39M – 76
2024
Q3 		$8.39M Sell
358,644
-1,502,633
-81% -$32.8M 0.67% 33
2024
Q2 		$33.1M Sell
1,861,277
-123,685
-6% -$1.97M 1.72% 19
2024
Q1 		$30.2M Buy
+1,984,962
New +$31.6M 1.68% 24
2021
Q1 		– Sell
-65,474
Closed -$3.41M – 76
2020
Q4 		$3.41M Sell
65,474
-184,927
-74% -$6.25M 0.2% 55
2020
Q3 		$6.7M Sell
250,401
-445,989
-64% -$10.3M 0.5% 36
2020
Q2 		$13.6M Buy
696,390
+421,085
+153% +$6.78M 0.86% 27
2020
Q1 		$2.71M Sell
275,305
-535,987
-66% -$6.77M 0.25% 48
2019
Q4 		$9.01M Sell
811,292
-922,336
-53% -$7.01M 0.65% 31
2019
Q3 		$9.73M Buy
1,733,628
+472,244
+37% +$3.29M 0.88% 28
2019
Q2 		$10.9M Buy
1,261,384
+909,573
+259% +$6.88M 1% 24
2019
Q1 		$2.83M Buy
+351,811
New +$1.9M 0.27% 53

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Sofinnova Investments's TGTX Position: Q4 2024 in Review

Sofinnova Investments sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 358,644 shares — an estimated $8.39M sold.

Sofinnova Investments first reported a position in TGTX in Q1 2019 and held it in 11 quarters. The position peaked at $33.1M in Q2 2024. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Sofinnova Investments reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Sofinnova Investments sold 358,644 TG Therapeutics shares in Q4 2024, an estimated $8.39M.
  • Sofinnova Investments first reported a position in TG Therapeutics in Q1 2019 and held it in 11 quarters.
  • Sofinnova Investments's TG Therapeutics position peaked at $33.1M in Q2 2024.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Sofinnova Investments's 13F filing for Q4 2024, filed 14 Feb 2025.